Leadership Transition at Viralgen: A New Era for AAV Gene Therapy

Viralgen, a prominent player in the field of adeno-associated virus (AAV) gene therapy manufacturing, has announced a pivotal leadership change as CEO Jimmy Vanhove prepares to transition to a new role within Bayer. Effective January 1, 2027, Angela Ochoa Chico will step in as the new CEO, marking an exciting new chapter for the organization.

A Seamless Transition

Jimmy Vanhove, who has successfully led the company for four years, will shift his focus to heading the development and expansion of Bayer’s U.S. Pharmaceutical Product Supply Network, located in New Albany, Ohio. This move is a testament to his significant contributions at Viralgen, where he played a pivotal role in its evolution from an emerging CDMO into a market leader in AAV gene therapy.

Angela Ochoa Chico comes with nearly two decades of experience in the pharmaceutical sector. Previously serving as the Product Supply Strategy Excellence Lead at Bayer, she has developed a robust background in operations, quality control, and manufacturing. In her role at Viralgen, she will be tasked with continuing the organization’s trajectory of innovation and excellence in gene therapy manufacturing.

Achievements Under Vanhove's Leadership

During Vanhove’s tenure, Viralgen has seen remarkable growth. The firm expanded its facilities and infrastructure, establishing itself as an end-to-end CDMO with a client base exceeding 70 global partners, including major pharmaceutical companies and foundations devoted to combating ultra-rare diseases. His focus on quality, operational reliability, and sustainability has been instrumental in improving the lives of patients living with rare conditions.

Viralgen currently operates one of the largest AAV manufacturing facilities worldwide, employing over 450 professionals in San Sebastián, Spain. The facility boasts cutting-edge technology and capabilities that span process development, clinical and commercial production, as well as in-house quality control testing. It emphasizes a commitment to providing high-quality, scalable gene therapy solutions efficiently.

Ochoa Chico's Vision for the Future

Angela Ochoa Chico expressed her excitement about taking the helm at Viralgen during a critical phase in its growth. She aims to enhance manufacturing capabilities while bolstering the company’s esteemed reputation for scientific excellence and innovation. Ochoa Chico’s extensive global perspective and experience in transforming pharmaceutical operations will be pivotal as she steers the company into its next chapter.

She acknowledged the strong foundation built under Vanhove’s leadership and reiterated her commitment to maintaining the company's focus on developing life-changing therapies for patients in need.

Conclusion

As Jimmy Vanhove prepares to embark on his new journey, a fresh set of eyes led by Angela Ochoa Chico will help sustain and build upon the legacy of Viralgen. The company is poised for continued success and innovation in the field of gene therapy, ensuring that it remains a trusted manufacturing partner for those striving to make a difference in patients’ lives worldwide. This transition reflects the dynamic nature of the pharmaceutical industry, driven by a mission to deliver transformative therapies to those who need them most.

For the latest updates about Viralgen and its developments, check their official website and social media channels.